{"disease":{"id":"thrombocytopenic-disorder","name":"Thrombocytopenic disorder","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"lusutrombopag","indication_name":"Thrombocytopenic disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mulpleta","generic_name":"LUSUTROMBOPAG","company_name":"Vancocin Italia","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Mulpleta works by binding to the thrombopoietin receptor, stimulating platelet production in the bone marrow."},{"drug_id":"avatrombopag","indication_name":"Thrombocytopenic disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doptelet","generic_name":"AVATROMBOPAG","company_name":"Akarx Inc","drug_phase":"marketed","molecular_target":"Thrombopoietin receptor","drug_class":"","quality_score":65,"revenue":null,"mechanism":"Doptelet works by binding to the thrombopoietin receptor, stimulating platelet production in the bone marrow."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06727669","title":"Longitudinal Cohort of Thrombosis and Hemostasis Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Peking University People's Hospital","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}